Close
Almac
Achema middle east

Drug Research

Pharma Future : Innovations In Drug Delivery Nanoparticles

The pharmaceutical sector is still a hub for new patent developments. The development of novel treatment paradigms, the severity of unfulfilled requirements, and the increasing significance of technology like pharmacogenomics, digital therapies, and artificial intelligence are what propel activity....

New Nickel Complex Revolutionizes Pharmaceutical Synthesis

The creation of a tool that can enable organic chemical processes that were not possible before has given the pharmaceutical business new ways to make effective drugs more quickly. In the past, most drugs were put together using alkyl building...

Speeding Up Toxicology Materials For Faster Drug Development

Quick delivery of toxicological materials According to Alejandro Fernandez Martell and James Berrie from Lonza, a bottleneck has developed in the supply of toxicological data to support INDs for novel therapies and, therefore, delivery of FIH studies, as a result...

ArisGlobal Extends Collaboration with Sitero for Drug Development Technology Platform

ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, and Sitero LLC, a next-generation clinical trial solutions provider, today announced an expansion of their strategic partnership. This collaboration integrates Sitero's unified eClinical technology platform...

Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing

Recipharm announced the launch of ReciPredict, a cutting-edge platform for Quality by Design (QbD), designed to transform the landscape of drug product development, tech transfer and manufacturing. With its innovative combination and systematic application of material sciences, statistical tools...

Radiopharmaceuticals : Rapid Growth And Rising Investments

The radiopharmaceutical industry is growing very quickly. In the past few years, there have been more mergers and acquisitions (M&A) and partnerships. Investors can find good business chances by learning more about this field. Recent mergers, purchases, and joint deals...

GSKs Lung Cancer ADC Earns FDA Breakthrough Designation

The FDA has granted breakthrough status to an antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion agreement last year. The pharma firm said that GSK5764227 (GSK'227, formerly known as HS-20093) has been granted the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »